THURSDAY, SEPTEMBER 27

1200-1800  REGISTRATION
Ballroom Foyer

1330-1430  WELCOME AND OPENING KEYNOTE LECTURE
Grand Ballroom I/II

1330-1340  Welcome from Scientific Committee Cochairs
Carlos L. Arteaga, UT Southwestern Simmons Cancer Center, Dallas, TX, USA
Carlos Gil Ferreira, Oncoclinicas Institute, São Paulo, Brazil
Gabriel A. Rabinovich, Instituto de Biologia y Medicina Experimental, CONICET, Buenos Aires, Argentina

1340-1345  Introduction
Carlos Gil Ferreira, Oncoclinicas Institute, São Paulo, Brazil

1345-1430  Genetic mechanisms of sensitivity and resistance to cancer immunotherapy
Drew M. Pardoll, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA

1430-1445  BREAK
Grand Ballroom Foyer

1445-1615  SESSION 1: IMMUNE CHECKPOINTS: MECHANISMS AND THERAPEUTIC OPPORTUNITIES
Grand Ballroom I/II

1445-1515  Targeting regulatory T cells within tumors: Means and mechanisms
Sergio A. Quezada, University College London Cancer Institute, London, United Kingdom

1515-1545  Modulating the right cell subpopulations for immunotherapy
Cristina B. Bonorino, Federal University for Health Sciences of Porto Alegre, Porto Alegre, Brazil and University of California, San Diego, San Diego, CA, USA

1545-1615  Immunotherapy for breast cancer: On the horizon
Leisha A. Emens, Johns Hopkins University School of Medicine, Baltimore, MD, USA
CONFERENCE PROGRAM

1615-1645  BREAK  
Grand Ballroom Foyer

1645-1815  SESSION 2: PRECISION CANCER MEDICINE
Grand Ballroom I/II

1645-1715  Immune biomarkers and patient selection in the treatment of NSCLC
Carlos H. Barrios, Centro de Pesquisa Clínica Hospital São Lucas, PUCRS, Porto Alegre, Brazil

1715-1745  Precision medicine in patients with metastatic breast cancer
Fabrice André, Institut Gustave Roussy, Villejuif, France

1745-1815  Implementing precision strategies to address molecular heterogeneity for gastroesophageal adenocarcinoma
Daniel V. Catenacci, University of Chicago, Chicago, IL, USA

1815-2030  OPENING RECEPTION  
Grand Ballroom Foyer

FRIDAY, SEPTEMBER 28

0845-0930  KEYNOTE LECTURE
Grand Ballroom I/II

Session Chair: Carlos L. Arteaga, UT Southwestern Simmon Cancer Center, Dallas, TX, USA

0845-0850  Introduction
Carlos L. Arteaga

0850-0930  Galectins: Emerging regulatory checkpoints linking immunity and angiogenesis in cancer
Gabriel A. Rabinovich, Instituto de Biología y Medicina Experimental, CONICET, Buenos Aires, Argentina

0930-0945  BREAK  
Grand Ballroom Foyer

0945-1115  SESSION 3: EPIGENETICS AND METABOLISM
Grand Ballroom I/II

0945-1015  Early metabolic reprogramming is a feature of gliomas and breast cancer
Elizabeth Maher, UT Southwestern Medical Center, Dallas, TX, USA

1015-1045  Epigenetic therapy regulates the tumor microenvironment to reduce immunosuppression and increase overall survival in a mouse model of ovarian cancer
Cynthia A. Zahn, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA

10  TRANSLATIONAL CANCER MEDICINE
1045-1115  Epigenetic deregulation in normal and malignant hematopoiesis
Maria E. Figueroa, Sylvester Comprehensive Cancer Center, University of Miami Miller
School of Medicine, Miami, FL, USA

1115-1130  BREAK
Grand Ballroom Foyer

1130-1230  SESSION 4: TRANSLATIONAL RESEARCH IN LEUKEMIA AND LYMPHOMA
Grand Ballroom I/II
1130-1200  Mantle cell lymphoma as a model for translational science
Eduardo Sotomayor, George Washington Cancer Center, Washington, DC, USA
1200-1230  Enhancing the function of CAR T cells by optimizing signaling
Marco L. Davila, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

1240-1310  CLINICAL TRIAL SPECIAL SESSION 1
Grand Ballroom I/II
12:40-1310  Neoadjuvant PD-1 blockade in resectable lung cancer
Drew M. Pardoll, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center,
Baltimore, MD

1320-1520  POSTER SESSION A / LUNCH
Grand Ballroom III and Foyer

1530-1700  SESSION 5: USE OF EX VIVO MODELS OF CANCER TO ADVANCE TREATMENT
Grand Ballroom I/II
1530-1600  Organoid modeling of cancer
Calvin Kuo, Stanford University, Stanford, CA, USA
1600-1630  Use of PDXs, CDXs, and syngeneic mouse models for personalized medicine
Maria Romina Girotti, Instituto de Biología y Medicina Experimental, CONICET,
Buenos Aires, Argentina
1630-1700  Title to be announced
Jos Jonkers, Netherlands Cancer Institute, Amsterdam, Netherlands

1700-1715  BREAK
Grand Ballroom Foyer
CONFERENCE PROGRAM

1715-1845  SESSION 6: VIRUS-INDUCED CANCERS: AN OPPORTUNITY FOR PREVENTION
Grand Ballroom I/II

1715-1745  HPV-associated oral malignancies in the new era of targeted and immune therapies
J. Silvio Gutkind, UCSD Moores Cancer Center, La Jolla, CA, USA

1745-1815  KSHV-activation of PDGFRA as an oncogenesis driver and therapeutic target in Kaposi’s sarcoma
Enrique A. Mesri, University of Miami Miller School of Medicine, Miami, FL, USA

1815-1845  Long noncoding RNAs and pseudogenes can distinguish at the molecular level adenocarcinoma from squamous cell carcinoma of the cervix
Luisa L. Villa, Fundação Faculdade de Medicina de São Paulo, São Paulo, Brazil

1845  EVENING OFF / DINNER ON OWN

SATURDAY, SEPTEMBER 29

0845-0930  KEYNOTE LECTURE
Grand Ballroom I/II
Session Chair: Gabriel A. Rabinovich, Instituto de Biología y Medicina Experimental, CONICET, Buenos Aires, Argentina

0845-0850  Introduction
Gabriel A. Rabinovich

0850-0930  Novel applications of cancer genomics
Luis A. Diaz, Jr., Memorial Sloan Kettering Cancer Center, New York, NY, USA

0930-0945  BREAK
Grand Ballroom Foyer

0945-1045  SESSION 7: THE MICROBIOME AND CANCER
Grand Ballroom I/II

0945-1015  Microbiota reconstitution restores intestinal integrity after cisplatin therapy
Jose R. Conejo-Garcia, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

1015-1045  Cancer and the microbiota
Giorgio Trinchieri, National Cancer Institute, Bethesda, MD, USA

1045-1100  BREAK
Grand Ballroom Foyer

1100-1230  SESSION 8: NUCLEAR STEROID RECEPTORS: TRANSLATIONAL IMPLICATIONS
Grand Ballroom I/II
Session Chair: Edith Kordon, IFIBYNE, Universidad de Buenos Aires, Buenos Aires, Argentina
1100-1130  
**Mechanisms of resistance to endocrine therapy**  
Myles Brown, Dana-Farber Cancer Institute, Boston, MA, USA

1130-1200  
**The ratio of progesterone receptor isoforms in breast cancer matters**  
Claudia Lanari, Instituto de Biología y Medicina Experimental, CONICET, Buenos Aires, Argentina

1200-1230  
**Targeting the bone compartment in metastatic prostate cancer**  
Nora M. Navone, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

1240-1310  
**CLINICAL TRIAL SPECIAL SESSION 2**  
Grand Ballroom I/II

1240-1310  
**Cyclin E1 (CCNE1) expression associates with benefit from palbociclib in metastatic breast cancer (MBC) in the PALOMA3 trial**  
Fabrice André, Institut Gustave Roussy, Villejuif, France

1320-1520  
**POSTER SESSION B / LUNCH**  
Grand Ballroom III and Foyer

1530-1700  
**SESSION 9: TARGETING TUMOR HETEROGENEITY: OBSTACLES AND OPPORTUNITIES**  
Grand Ballroom I/II

1530-1600  
**Disseminated cancer cells dormancy: How it might impact metastasis prevention**  
Julio A. Aguirre-Ghiso, Icahn School of Medicine at Mount Sinai, New York, NY, USA

1600-1630  
**Title to be announced**  
Jorge S. Reis-Filho, Memorial Sloan Kettering Cancer Center, New York, NY, USA

1630-1700  
**Title to be announced**  
Dirce Maria Carraro, A.C.Camargo Cancer Center, São Paulo, Brazil

1700-1715  
**CLOSING REMARKS**  
Grand Ballroom I/II

Carlos L. Arteaga, UT Southwestern Simmons Cancer Center, Dallas, TX, USA

Carlos Gil Ferreira, Oncoclinicas Institute, São Paulo, Brazil

Gabriel A. Rabinovich, Instituto de Biología y Medicina Experimental, CONICET, Buenos Aires, Argentina